COMMUNIQUÉS West-GlobeNewswire

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
11/06/2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive [...]
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
11/06/2026
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists [...]
Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the 1-for-5 reverse stock split (“ [...]
BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return
11/06/2026
ELLON, Scotland, June 11, 2026 (GLOBE NEWSWIRE) -- BrewDog , one of the U.K.’s leading and most recognizable craft beer brands, part of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is rolling pint prices back to [...]
Spinach® is the Number One Vape Brand in Canada
11/06/2026
Spinach® vapes, known for exceptional quality, bold flavor profiles and advanced hardware, continue to resonate with adult consumers across Canada TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: [...]
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
11/06/2026
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorder Five scientific presentations will feature preclinical and clinical data [...]
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
11/06/2026
BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with favorable pharmacokinetic properties SAN [...]
Pharvaris Announces Annual General Meeting of Shareholders
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
What Science-Backed Subscription Health Programs Measure Differently
11/06/2026
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the [...]
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
11/06/2026
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall [...]
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
11/06/2026
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES [...]
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
11/06/2026
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab – – [...]
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
11/06/2026
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine therapy for women [...]
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
11/06/2026
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026) [...]
Clinical Data Showed Average 67% Pain Score Reduction and 50% Gain in Walking Distance with Cartigenix HP® in 90 Days*†
11/06/2026
A randomized, placebo-controlled study published in Pharmaceutical Research documented a 64% reduction in WOMAC pain scores and measurable cartilage regeneration biomarkers at 90 days, a first for the joint health [...]
Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com
11/06/2026
My Grief Angels Inc. launches a first-of-its-kind Father’s Day grief support initiative — a complete, free bundle of resources assembled by bereaved mothers, for bereaved fathers. New York, NY, June 11, 2026 (GLOBE [...]
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
11/06/2026
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With [...]
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
11/06/2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, today announced that [...]
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
11/06/2026
Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the [...]

Pages